Safety, tolerability, and immunogenicity of a CpG/Alum adjuvanted SARS-CoV-2 recombinant protein vaccine (ZR202-CoV) in healthy adults: Preliminary report of a phase 1, randomized, double-blind, placebo-controlled, dose-escalation trial

• Main Authors: Guang-Wei Feng (Author), Zhong-Fang Wang (Author), Peng He (Author), Qin-Ying Lan (Author), Ling Ni (Author), Ya-Zheng Yang (Author), Chen-Fei Wang (Author), Ting-Ting Cui (Author), Li-Li Huang (Author), Yong-Qiang Yan (Author), Zhi-Wei Jiang (Author), Qing Yang (Author), Bang-Wei Yu (Author), Xi Han (Author), Jing-Jing Chen (Author), Shu-Yuan Yang (Author), Lin Yuan (Author), Ling-Yun Zhou (Author), Ge Liu (Author), Ke Li (Author), Zhen Huang (Author), Jin-Cun Zhao (Author), Zhong-Yu Hu (Author), Zhi-Qiang Xie (Author)
• Format: Book
• Published: Taylor & Francis Group, 2023-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

This was a phase 1 dose-escalation study of ZR202-CoV, a recombinant protein vaccine candidate containing a pre-fusion format of the spike (S)-protein (S-trimer) combined with the dual-adjuvant system of Alum/CpG. A total of 230 participants were screened and 72 healthy adults aged 18-59 years were...